<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TIAGABINE HYDROCHLORIDE</span><br/>(ti-a'ga-been)<br/><span class="topboxtradename">Gabitril Filmtabs<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">anticonvulsant</span>; <span class="classification">gaba inhibitor</span><br/><b>Prototype: </b>Valproic acid sodium (sodium valproate)<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2 mg, 4 mg, 12 mg, 16 mg, 20 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>GABA inhibitor for the treatment of partial epilepsy. Potent and selective inhibitor of GABA uptake into presynaptic neurons;
         allows more GABA to bind to the surfaces of postsynaptic neurons in the CNS.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effectiveness indicated by reduction in seizure activity.</p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunctive therapy for partial seizures.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to tiagabine; pregnancy (category C).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Liver function impairment; lactation; history of spike and wave discharge on EEG; status epilepticus.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Seizures</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 4 mg q.d., may increase dose by 48 mg/d qwk (max: 56 mg/d in 24 divided doses)<br/><span class="rdage">Adolescent:</span> <span class="rdroute">PO</span>
<i>1218 y,</i> Start with 4 mg q.d., after 2 wk may increase dose by 48 mg/d qwk (max: 32 mg/d in 24 divided doses)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food.</li>
<li>Make dosage increases, when needed, at weekly intervals.</li>
<li>Store at 15°30° C (59°86° F) in a tightly closed container and protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Infection, flu-like syndrome, pain, myasthenia, allergic reactions, chills, malaise, arthralgia. <span class="typehead">CNS:</span>
<span class="speceff-common">Dizziness, asthenia, tremor, somnolence, nervousness,</span> difficulty concentrating, ataxia, depression, insomnia, abnormal gait, hostility, confusion, speech disorder, difficulty
      with memory, paresthesias, emotional lability, agitation, dysarthria, euphoria, hallucinations, hyperkinesia, hypertonia,
      hypotonia, myoclonus, twitching, vertigo. Risk of new-onset seizures. <span class="typehead">CV:</span> Vasodilation, hypertension, palpitations, tachycardia, syncope, edema, peripheral edema. <span class="typehead">GI:</span> Abdominal pain, diarrhea, nausea, vomiting, increased appetite, mouth ulcers. <span class="typehead">Respiratory:</span> Pharyngitis, cough, bronchitis, dyspnea, epistaxis, pneumonia. <span class="typehead">Skin:</span> Rash, pruritus, alopecia, dry skin, sweating, ecchymoses. <span class="typehead">Special Senses:</span> Amblyopia, nystagmus, tinnitus. <span class="typehead">Urogenital:</span> Dysmenorrhea, dysuria, metrorrhagia, incontinence, vaginitis, UTI. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Carbamazepine,</b>
<b>phenytoin,</b>
<b>phenobarbital</b> decrease levels of tiagabine. Use with <span class="classification">antidepressants</span>, <span class="classification">antipsychotics</span>, <span class="classification">stimulants</span>, and <span class="classification">narcotics</span> may increase seizure risk. <span class="typehead">Herbal:</span>
<b>Ginkgo</b> may decrease anticonvulsant effectiveness. <b>Evening primrose</b> oil may affect seizure threshold. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed; 90% bioavailability. <span class="typehead">Peak:</span> 45 min. <span class="typehead">Distribution:</span> 96% protein bound. <span class="typehead">Metabolism:</span> Metabolized in liver, probably by cytochrome P450 3A isoform. <span class="typehead"> Elimination:</span> 25% excreted in urine, 63% excreted in feces. <span class="typehead">Half-Life:</span> 79 h (47 h with other enzyme-inducing drugs). 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Measure plasma levels of tiagabine before and after changes are made in the drug regimen.</li>
<li>Be aware that concurrent use of other anticonvulsants may decrease effectiveness of tiagabine or increase the potential for
            adverse effects.
         </li>
<li>Monitor carefully for S&amp;S of CNS depression.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not stop taking drug abruptly; may cause sudden onset of seizures.</li>
<li>Exercise caution while engaging in potentially hazardous activities because drug may cause dizziness.</li>
<li>Use caution when taking other prescription or OTC drugs that can cause drowsiness.</li>
<li>Report any of the following to the physician: Rash or hives; red, peeling skin; dizziness; drowsiness; depression; GI distress;
            nervousness or tremors; difficulty concentrating or talking.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>